PCSA

Processa Pharmaceuticals Inc

PCSA, USA

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine, which is in Phase 2 clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 that is in Phase 2B clinical trials for treatment of gastroparesis; and PCS499 for the treatment of glomerular disease. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2017 and is based in Hanover, Maryland.

https://www.processapharmaceuticals.com

Stock Price

$0.00

0%

increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
PCSA
stock
PCSA

How PCSA stock reacts to global recession fears - Watch List & Consistent Profit Trading Strategies bollywoodhelpline.com

Read more →
PCSA
stock
PCSA

Alliance Entertainment and Processa Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV heraldmailmedia.com

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

HOLD

Target Price:

$25

Analyst Picks

Strong Buy

0

Buy

0

Hold

1

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

1.02

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-58.91 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-45.31 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very High

0.30

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 0.80% of the total shares of Processa Pharmaceuticals Inc

1.

Virtu Financial LLC

(0.1876%)

since

2025/06/30

2.

UBS Group AG

(0.1158%)

since

2025/06/30

3.

Alpine Partners VI, LLC

(0.0957%)

since

2025/06/30

4.

Geode Capital Management, LLC

(0.0906%)

since

2025/06/30

5.

Cubist Systematic Strategies, LLC

(0.075%)

since

2025/06/30

6.

Fidelity Extended Market Index

(0.0524%)

since

2025/07/31

7.

Vanguard Group Inc

(0.0438%)

since

2025/06/30

8.

Fidelity Series Total Market Index

(0.0374%)

since

2025/07/31

9.

Jane Street Group LLC

(0.0345%)

since

2025/06/30

10.

Vanguard Institutional Extnd Mkt Idx Tr

(0.0301%)

since

2025/07/31

11.

Sequoia Financial Advisors LLC

(0.0197%)

since

2025/06/30

12.

Tower Research Capital LLC

(0.0044%)

since

2025/06/30

13.

Northern Trust Extended Eq Market Idx

(0.0019%)

since

2025/06/30

14.

NT Ext Equity Mkt Idx Fd - L

(0.0019%)

since

2025/06/30

15.

State St US Extended Mkt Indx NL Cl C

(0.001%)

since

2025/08/31

16.

Fidelity Total Market Index

(0.0008%)

since

2025/07/31

17.

NT Ext Equity Mkt Idx Fd - NL

(0.0006%)

since

2025/06/30

18.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.0005%)

since

2025/06/30

19.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0004%)

since

2024/12/31

20.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0004%)

since

2025/06/30

21.

SSgA U.S. Total Market Index Strategy

(0.0004%)

since

2025/03/31

22.

Wells Fargo & Co

(0.0003%)

since

2025/06/30

23.

Bank of America Corp

(0.0002%)

since

2025/06/30

24.

State St US Ttl Mkt Indx NL Cl A

(0.0001%)

since

2025/08/31

25.

Northern Trust Wilshire 5000

(0.0001%)

since

2025/06/30

26.

SBI Securities Co Ltd

(0%)

since

2025/06/30

27.

Advisor Group Holdings, Inc.

(0%)

since

2025/06/30

28.

Miracle Mile Advisors, INC.

(0%)

since

2025/06/30

29.

Armistice Capital, LLC

(0%)

since

2025/06/30

30.

HRT FINANCIAL LLC

(0%)

since

2025/03/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.07

EPS Estimate

-0.45

EPS Difference

0.38

Surprise Percent

84.4444%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(6)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.3)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
Moderate Momentum(3.5)
Net Net
Possible Net-Net(3.5)
Quality
Low Quality Business(3)
Value
Undervalued(6.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.